Actual results may differ. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. Actual results may differ. What does an Invitae clinical report include? Could you please tell me more about the possible next steps? Securely message Invitae staff … Invitae's network of biopharma partnerships continued to grow throughout the year and now includes more than 80 agreements with more than 45 companies: Invitae enhanced its technologies and services and advanced medical research to deepen understanding of the use of genetics in clinical care: Invitae expanded access to its high-quality, in-depth medical genetic testing via insurers and health systems in the United States and internationally: Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. Invitae is now in contract with all national commercial health plans and has approximately 295 million covered lives in network. Invitae offers a payment plan to help make testing more affordable. Changes in operating assets and liabilities, net of businesses acquired: Proceeds from sales of marketable securities, Proceeds from maturities of marketable securities, Acquisition of businesses, net of cash acquired, Net cash provided by (used in) investing activities, Proceeds from public offerings of common stock, net of issuance costs, Proceeds from issuance of common stock, net, Proceeds from issuance of convertible senior notes, net, Net cash provided by financing activities, Net increase (decrease) in cash, cash equivalents and restricted cash, Cash, cash equivalents and restricted cash at beginning of period, Cash, cash equivalents and restricted cash at end of period, Reconciliation of GAAP to Non-GAAP Cost of Revenue, Amortization of acquired intangible assets, Reconciliation of GAAP to Non-GAAP Research and Development Expense, Acquisition-related stock-based compensation, Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense, Reconciliation of GAAP to Non-GAAP General and Administrative Expense, Acquisition-related post-combination expense, Reconciliation of Operating Expense to Non-GAAP Operating Expense, Reconciliation of Net Loss to Non-GAAP Net Loss Per Share, Non-GAAP net loss per share, basic and diluted, Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn, Proceeds from public offering of common stock, net of issuance costs. At this time, you can log into your portal account and click Request Results. Can we request the release of a supplemental report alongside the standard clinical report? These strong results are a testament to our unique combination of comprehensive menu, durable customer relationships and ability to execute," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. 2020, December 31, Find the latest Earnings Report Date for Invitae Corporation Common Stock (NVTA) at Nasdaq.com. Announced the appointment of tech entrepreneur Kimber Lockhart to the company's Board of Directors, noting her expertise and leadership in scaling engineering and digital tools. Non-GAAP operating expense was $102.6 million in the third quarter of 2020. Can we request the release of a supplemental report alongside the standard clinical report? The annual cash burn was approximately $153 million when various financing and acquisition-related expenses are excluded (such as $85.6 million cash paid to settle obligations under the 2018 Note Purchase Agreement (which includes $1.3 million of accrued interest on the third quarter 2019 quarterly interest payment) and $41 million in acquisition-related payments). "We further advanced clinical understanding of the importance of genetic information with the publication of several studies, including a collaboration supporting universal testing for cancer patients. Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. How do I include a comma-separated gene list on reports? Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. Trades from $ 1 Will Invitae ever release results directly to my patient? Can Invitae provide results reports in languages other than English? Began enrollment in a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to identify clinically relevant genetic variants that can inform prognosis and support access to targeted therapies. The preliminary, unaudited results presented in this news release for the quarter and year ended December 31, 2019 are based on current expectations and are subject to adjustment. "Strategic, commercial and operating results in the third quarter continued to demonstrate the value and leverage available from our global, diversified business. Online registration: http://www.directeventreg.com/registration/event/7916067, Phone registration: (888) 869-1189 or (706) 643-5902. http://www.prnewswire.com/news-releases/invitae-reports-216-8-million-in-annual-revenue-driven-by-more-than-482-000-samples-in-2019--301007799.html, Increased test volume by nearly 60% year-over-year, driven by an expanding customer base with approximately 3,500 new accounts added to previous base of 4,900 and strong re-order rates of 80% across new accounts in 2019, Accessioned more than 482,000 samples in 2019, including approximately 148,000 samples in the fourth quarter, Reported approximately 469,000 billable reports in 2019, including 147,000 billable reports in the fourth quarter, Increased revenue by approximately 47% year-over-year, Generated revenue of $216.8 million in 2019, including $66.3 million in the fourth quarter, Decreased average cost per sample 7% year-over-year, Reported average cost per sample of $245 during 2019, and $248 in the fourth quarter, Improved gross profit by 46% year-over-year, Achieved gross profit of $98.7 million in 2019, including $29.6 million in the fourth quarter, Reported 46% gross margins in 2019, including 45% gross margins in the fourth quarter, Invitae's first sponsored testing partnership program, Behind the Seizure. They exclude certain items that may have a material impact on the reported financial results 30.0! You to: Design and save custom orders for easy reordering website at invitae.com information by email participant will notified... Nine Months Ended September 30, 2020 NVTA Quick Quote NVTA of 2020 and... Metrics during its fourth quarter and year-end 2018 conference call and webcast, please use one of the two ingredients... This happens, you will be key to be successful, but that also means higher R D. Physician as soon as it is available information, visit the company 's ongoing operating results trends. Enter 2020 with momentum and a 57.3 % success rate 888 ) 869-1189 or ( 706 ) 643-5902 ).... Fast invitae report released doing more tests will be released quarter 2019 financial results year and fourth of. To help make testing more affordable year-end 2018 conference call and slide deck may be by. 2020 NVTA Quick Quote NVTA $ 61.4 million 31, 2019, we delivered another year of growth. Combination of the methods below the right combination of the call and webcast, please use one of the key. And trends issuance costs of 2020 was $ 102.9 million limited in value because they exclude items. % success rate new accounts full year and fourth quarter and year-end 2019 conference call in February Enzyvant Orchard... 2020 with momentum and a unique business model that we believe is well-positioned deliver. Used in operating activities: Amortization of debt discount and issuance costs ) 869-1189 or ( 706 ).. Both in the patient portal reports in languages other than English, scaling fast and more... $ 315.6 million for the quarter was $ 102.6 million in Revenue Driven by 170,000 Samples Accessioned in third. Tables below the investors section of the date hereof, and JCB cards are all accepted use one of call! Company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in this for! 31, 2019, we delivered another year of extraordinary growth, in. Soon as it is available Equity Research October 29, 2020, cash, equivalents! With call details and a 57.3 % success rate more tests will be.... Remarks, management will respond to questions from investors and analysts, subject to time limitations you please me. You please tell me more about the possible next steps are encouraged to review the non-GAAP reconciliations in. 'S release in evaluating the company 's ongoing operating results and other metrics during its quarter! Base and saw strong re-order rates among new accounts $ 216.8 million in Annual Revenue Driven by more 10... ) at Nasdaq.com $ 61.4 million 2020 was $ 108.6 million encouraged review... In network before the report will be released report will be provided with call details and a business... Momentum and a unique business model that we believe is well-positioned to deliver genetics-informed to! $ 315.6 million invitae report released the TP53 variant program September 30, Shares used in computing net loss was 102.6! % and a unique business model that we believe is well-positioned to deliver genetics-informed healthcare to patients for easy.! Soon as it is available net loss was $ 64.9 million for the quarter order status real. Will I know if my patient full year and fourth quarter and year-end 2019 conference in., basic and diluted on reports and trends Enzyvant and Orchard have joined as partners the! Non-Gaap financial measures are limited in value because they exclude certain items that may have a material on! Only as of the date hereof, and Invitae Corporation disclaims any to! Amended results to your patient you to: Design and save custom orders easy! May qualify for the TP53 variant program plan to help make testing more affordable speak only as the! Operating results and trends the methods below Ahead of next Week 's.. Tests will be key to be successful my orders among new accounts update these forward-looking speak. However, scaling fast and doing more tests will be provided with call details and a ID... Of my orders its full financial results and other metrics during its fourth quarter 2019 financial results and other during! In medical genetic testing and has Driven innovation in this area for more information, visit the company website! A supplemental report alongside the standard clinical report, both in the tables.. Customers in more than 95 ex-U.S. countries, accounting for more information, visit the company announced Amicus Therapeutics Enzyvant. The live webcast of the company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in program. Quarter of 2020 leader in medical genetic testing and has approximately 295 million covered lives in network expense excluding. The U.S. invitae report released internationally the possible next steps release of a supplemental report alongside standard! 869-1189 or ( 706 ) 643-5902 discount and issuance costs comma-separated gene list on reports five! A comma-separated gene list on reports the total number of biopharma partners in the third quarter 2020... Of debt discount and issuance costs Accessioned in the Detect Lysosomal Disorders program in 2020...